| Company Name: | Genitope Corporation | | Ticker Symbol: | GTOP | | | WWW Address: | www.genitope.com | | CEO: | Dr. Dan W. Denney Jr., Ph.D. | | No. of Employees: | 206 | | Common Issue Type: | CS | | Business Description: | A biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 0.08 |  0.0 | - | - | 0 | 0.12 | 0.06 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 3.4 | 43.0 | 1.13 | -1.63 | 0.00 | 0.0 | 0.0 | 77.50 - 0.04 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 0.08 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 3.4 | mil |
| Latest Shares Outstanding | 43.0 | mil |
| Earnings pS (EPS) | -1.63 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 0 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 32.7 | mil |
| Float as % of Shares Outstanding | 76.1 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 0.00 | % |
| Research & Devlopment (R&D) as % of Revenue | 0.00 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.0 | % |
| Return on Assets (ROA) | -160.9 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -193.6 | % |
| Current Ratio | 1.3 | |
| Leverage Ratio (Assets/Equity) | 6.4 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 4.70 | |
| LT Debt/Total Capital | 81.0 | % |
| Working Capital pS | 0.08 | $ |
| Cash pS | 0.27 | $ |
| Book-Value pS | 0.24 | $ |
| Tangible Book-Value pS | 0.24 | $ |
| Cash Flow pS | -2.24 | $ |
| Free Cash Flow pS | -0.93 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.33 | |
| Price/Tangible Book Ratio | 0.33 | |
| Price/Cash Flow | 0.0 | |
| Price/Free Cash Flow | -0.1 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -42.9 | 57 | 5,885 | 46,157 |
| 4 Weeks | 0.20 | 0.06 | 0.06 | 33.3 | 129 | 5,252 | 105,044 |
| 13 Weeks | 0.20 | 0.04 | 0.11 | -27.3 | 80 | 3,430 | 216,071 |
| 26 Weeks | 0.79 | 0.04 | 0.78 | -89.7 | 11 | 3,941 | 496,538 |
| 52 Weeks | 77.50 | 0.04 | 3.71 | -97.8 | 2 | 5,454 | 1,369,011 |
| YTD | 77.50 | 0.04 | - | -89.2 | 12 | 4,277 | 675,825 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 0.11 | 0.12 | 0.08 | 0.26 | 0.96 | 1.13 | 0.95 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 0.00 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 125.63 | NA | 157.39 |
| R&D | 25.42 | NA | 30.55 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 0.0 | 0.0 | 0.0 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | -0.83 | -0.83 | -0.24 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 17.18 |
| Current Ratio | 3.6 |
| Quick Ratio (Acid Test) | 3.4 |
| Liquidity Ratio (Cash) | 3.32 |
| Receivables Turnover | 0.0 |
| Average Collection Period | 0 |
| Working Capital/Equity | 31.3 |
| Working Capital pS | 0.48 |
| Cash-Flow pS | -1.36 |
| Free Cash-Flow pS | -1.38 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -2.17 |
| Financial Leverage Ratio (Assets/Equity) | 1.8 |
| Debt Ratio | 45.2 |
| Total Debt/Equity (Gearing Ratio) | 0.73 |
| LT Debt/Equity | 0.70 |
| LT Debt/Capital Invested | 41.2 |
| LT Debt/Total Liabilities | 85.1 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 4.59 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.13 |
| Tobin's Q Ratio | 0.03 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -0.57 |
| Enterprise Value (EV)/Free Cash Flow | 0.40 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 0.33 |
| Price/Book Ratio - LTM | 0.33 |
| Price/Cash Flow Ratio | 0.0 |
| Price/Free Cash Flow Ratio - LTM | -0.1 |
| Price/Sales Ratio | 0.00 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 1.08 |
| Current Liabilities pS | 0.19 |
| Tangible Book Value pS - LTM | 0.24 |
| Book Value pS - LTM | 0.24 |
| Capital Invested pS | 2.62 |
| Cash pS - LTM | 0.27 |
| Cash Flow pS - LTM | -2.24 |
| Free Cash Flow pS - LTM | -0.93 |
| Earnings pS (EPS) | -1.63 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 0.00 |
| Free Cash Flow Margin 5YEAR AVG | 0.00 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.00 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.00 |
| Return on Capital Invested (ROCI) | -58.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -40.0 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -54.4 |
| Return on Assets (ROA) - 5YEAR AVRG. | -36.9 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 0 |
| Revenue per Employee | 0 |
| Net Income per Employee | -318,675 |
| Average Collection Period | 0 |
| Receivables Turnover | 0.0 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 0.00 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.00 |
| Fixed Assets Turnover | 0.00 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.00 |
| Revenue per $ Plant | 0.00 |
| Revenue per $ Common Equity | 0.00 |
| Revenue per $ Capital Invested | 0.00 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 0.0 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
| Research & Devlopment (R&D) as % of Revenue | 0.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
|
|  
|
| |
 |  |